title: Oral altretamine used as salvage therapy in recurrent ovarian cancer.
abstract: BACKGROUND
  Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy. This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine.
  
  
  METHODS
  Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery. Both women were subsequently treated with platinum-based chemotherapy. One had persistent cancer documented 2 months post therapy, while the other was disease-free for 22 months before recurring. Both received altretamine in a salvage setting. Each of these women achieved a prolonged response to third-line altretamine therapy, and one of whom was disease-free for 4 years and the other remains disease-free over 7 years following initiation of salvage therapy.
  
  
  CONCLUSIONS
  Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity.
authors.affiliation: Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305-5317, USA.
authors.forename: John K
authors.initials: JK
authors.lastname: Chan
authors.forename: Vera
authors.initials: V
authors.lastname: Loizzi
authors.forename: Alberto
authors.initials: A
authors.lastname: Manetta
authors.forename: Michael L
authors.initials: ML
authors.lastname: Berman
mesh_terms: D000284:Administration, Oral; D000368:Aged; D006585:Altretamine / Q000008:administration & dosage*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating; D006585:Altretamine